ArticleJournal of neurosurgery. Spine2025
The impact of systemic and radiation therapy in patients undergoing spine surgery for metastatic breast cancer: a dual-institution study.
Article in Journal of neurosurgery. Spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveAlthough targeted systemic therapies and postoperative radiation therapy (RT) have improved outcomes in patients with metastatic breast cancer, how treatment combinations impact spine surgery outcomes remains understudied. In patients undergoing spine surgery for metastatic breast cancer, the authors sought to do the following: 1) describe patterns of postoperative therapy; 2) report perioperative outcomes; and 3) evaluate the impact of the treatment plan on local recurrence (LR) and overall survival (OS).
methodsA dual-institution, retrospective cohort study of patients undergoing spine surgery for metastatic breast cancer was undertaken. Patients were divided into 4 groups based on the postoperative treatment: systemic therapy alone, RT alone, combined, or neither. Patients were also classified by their breast cancer molecular subtype: HR+/HER2+, HR+/HER2-, HR-/HER2+, or TNBC. Preoperative data were used to calculate commonly cited spine surgery prognostic scores. Perioperative and survival outcomes were evaluated. Chi-square, ANOVA, log-rank, and Cox regression tests were performed.
resultsIn this cohort of 66 patients undergoing spine surgery for metastatic breast cancer, the majority received combined systemic therapy and RT (59.1%), with fewer receiving systemic therapy alone (18.2%), RT alone (7.6%), or neither (15.2%). There was a significant difference based on the type of postoperative therapy in having a motor deficit on presentation (p = 0.004; V = 0.448), preoperative Karnofsky Performance Scale score (p = 0.012; η2 = 0.160), and preoperative American Spinal Injury Association Impairment Scale score (p = 0.015; V = 0.329). Patients who received RT alone or neither therapy presented at a higher rate with a motor deficit and tended to have worse preoperative Karnofsky Performance Scale and American Spinal Injury Association Impairment Scale scores compared to those who received combined or systemic-only treatment. No significant differences in prognostic scores were detected between molecular subtypes. Patients who underwent any postoperative treatment had a longer OS (combined, 4.23 years; systemic, 3.78 years; RT, 5.15 years) than patients who received neither (0.26 years). No significant difference was observed in LR. Multivariable Cox regression revealed that any adjuvant treatment significantly improved survival compared to no treatment: combined, hazard ratio 0.041 (95% CI 0.009%-0.169%), p < 0.0001; systemic, hazard ratio 0.073 (95% CI 0.016%-0.316%), p = 0.0006; and RT, hazard ratio 0.139 (95% CI 0.016%-0.848%), p = 0.0431, whereas readmission within 90 days following surgery significantly worsened survival: hazard ratio 5.372 (95% CI 1.753%-15.895%), p = 0.0024.
conclusionsIn this dual-institution study of patients undergoing spine surgery for metastatic breast cancer, any treatment with systemic therapy and/or RT was associated with improved OS but not LR. Spine surgeons should work collaboratively with oncologists and radiation oncologists to ensure that treatment is started as soon as safely possible after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.